AARTI DRUGS LTD.

Aarti Drugs Ltd announced that the Hon'ble Supreme Court of India has dismissed the Special Leave Petition filed by the GST Department. This petition challenged a previous order by the High Court of Judicature at Bombay, which had set aside an order by the CGST & C.Ex. Authority. The original dispute involved a Show Cause Notice for alleged contravention of Rule 96(10) of CGST Rule, proposing a demand of IGST of ₹230.70 Crores, along with interest and penalty. The CGST & C.Ex. Authority had previously ordered a demand of ₹20.72 Crores for erroneous IGST refund and imposed a penalty of ₹20.72 Crores. The Supreme Court's dismissal means the matter is now disposed of in favor of Aarti Drugs. The company stated there is no financial, operational, or other impact as the order is in their favor.

Aarti Drugs Limited reported its unaudited financial results for the quarter ended June 30, 2026. Total revenue increased by 19% year-on-year to ₹703.6 crore from ₹590.8 crore in Q1 FY26. EBITDA grew by 30% YoY to ₹96.9 crore, with EBITDA margin expanding by 120 basis points to 13.8%. Profit Before Tax (PBT) rose 35% YoY to ₹69.2 crore. However, Profit After Tax (PAT) saw a 7% decline to ₹50.1 crore, impacted by a principal tax refund of approximately ₹15 crores in Q1 FY26. The company highlighted strong performance in Specialty Chemicals, with revenue up 150% YoY. Management cited volume growth, improved realizations, operational efficiencies, and product mix optimization as key drivers.

Aarti Drugs Ltd announced the revocation of a closure order issued by the Gujarat Pollution Control Board (GPCB) for its plant located at Sayakha. The GPCB had previously issued closure directions under Section 33A of the Water Act due to observed non-compliances during an inspection on June 20, 2026. The company applied for revocation, which has now been granted, allowing operations to continue. As an interim measure, the GPCB has levied an Environmental Damage Compensation (EDC) of ₹10,20,000/- under the 'Polluter Pays' Principle. The company states there is no impact on its financial or operational activities.

Aarti Drugs Limited announced a leadership transition effective October 1, 2026. Shri Rashesh C. Gogri will be elevated to Chairman, in addition to his role as Managing Director. Shri Adhish P. Patil will be appointed as the new Managing Director. This transition sees Shri Prakash M. Patil retiring as Chairman, Managing Director & CEO, after a long association with the company since its inception. He will continue to provide guidance and strategic support during the transition. The changes are aimed at strengthening governance and ensuring long-term strategic growth, building on the company's manufacturing scale, R&D capabilities, and customer relationships. The leadership transition is not expected to alter the company's long-term strategic direction.

Aarti Drugs Ltd. announced a significant leadership transition following a Board Meeting on July 31, 2026. Shri Prakash M. Patil, the current Chairman, Managing Director, and CEO, will retire from his position effective September 30, 2026, citing a desire for early retirement and an orderly leadership transition. He has been associated with the company since its inception. Shri Rashesh C. Gogri, currently the Managing Director, will be elevated to the role of Chairman from October 1, 2026, while retaining his existing MD position. Additionally, Shri Adhish P. Patil, the Chief Financial Officer, will be appointed as the Managing Director for a five-year term, effective October 1, 2026, subject to shareholder approval. The Board also approved the appointment of Shri Nilesh B. Patil as Whole-time Director and the re-appointment of Shri Harshit M. Savla as Joint Managing Director, Shri Harit P. Shah as Whole-time Director, and three Independent Directors (Shri Hasmukh B. Dedhia, Shri Ajit E. Venugopalan, and Shri Sandeep M. Joshi) for second terms.

Aarti Drugs Ltd's Board of Directors, at its meeting on July 31, 2026, considered and approved the Audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026 (Q1 FY27). The company informed that the Statutory Auditors have carried out the audit and expressed an unmodified audit opinion on these financial results. The results will be published in newspapers as per SEBI regulations and made available on the company's website and stock exchange platforms. The board meeting commenced at 2:30 PM and concluded at 5:20 PM. An exceptional item related to the write-off of Capital Work-in-Progress was noted in the results.

Aarti Drugs Ltd announced its audited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors approved these results in a meeting held on July 31, 2026. The company has made arrangements to publish the financial results in newspapers as per SEBI regulations. The financial results were reviewed by the Audit Committee and the Board of Directors, with statutory auditors providing an unmodified audit opinion. The company operates in a single business segment: pharmaceuticals.

Aarti Drugs Ltd has announced that its Board of Directors will convene on July 31, 2026. The primary agenda item for this meeting is to consider and approve the Audited Financial Results for the quarter ended June 30, 2026. Following the declaration of these results, the company's trading window will be closed for 48 hours. The company has also made this information available on its official website.

Aarti Drugs Ltd has received closure directions from the Gujarat Pollution Control Board (GPCB) for its manufacturing plant located in Saykha Industrial Estate, Bharuch, Gujarat. The directive, issued under the Water Act, mandates the closure of Amines manufacturing operations effective 15 days from the issuance of the letter, following observations of non-compliances during a GPCB inspection on June 20, 2026. The company states there is no immediate financial or operational impact as corrective measures are being taken, and a response is being prepared for revocation. Operations at other manufacturing units remain unaffected.

Aarti Drugs Ltd has filed a disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, detailing changes in shareholding by Dilesh Roadlines Pvt Ltd and other promoters/promoter group entities. The filing indicates a net decrease in the promoter group's shareholding. Specifically, Dilesh Roadlines Private Limited saw a reduction of 125,998 shares, and other promoters collectively sold 1,769,641 shares through market sales, while acquiring 370,156 shares via market purchases. The total promoter group shareholding decreased by 2,265,795 shares, resulting in a revised total holding of 49,681,228 shares, representing 54.03% of the total share capital. The total share capital of the company was adjusted due to a buyback of 665,000 shares.